HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Final Thoughts on Progress in Breast Cancer Research

June 16th 2017

Immunotherapy for Triple-Negative Breast Cancer

June 16th 2017

PARP Inhibitors for BRCA-Mutated TNBC

June 16th 2017

BRCA-Mutated Triple-Negative Breast Cancer

June 16th 2017

Metastatic Triple-Negative Breast Cancer

June 16th 2017

Brain Metastases in HER2-Positive Breast Cancer

June 16th 2017

Triple-Positive Metastatic Breast Cancer

June 16th 2017

Adjuvant Therapy for High-Risk HER2+ Breast Cancer

June 16th 2017

Pending FDA Approval of Neratinib in HER2+ Breast Cancer

June 16th 2017

APHINITY Trial in HER2+ Breast Cancer

June 16th 2017

Extended Adjuvant Therapy for HER2-Positive Breast Cancer

June 16th 2017

Adjuvant Therapy for HER2-Driven Breast Cancer

June 16th 2017

PI3K Inhibitors for HR+ Metastatic Breast Cancer

June 16th 2017

Sequencing in Hormone-Driven Metastatic Breast Cancer

June 16th 2017

Endocrine Resistance in HR+ Metastatic Breast Cancer

June 16th 2017

Emerging CDK4/6-Targeted Therapy for Breast Cancer

June 16th 2017

Choosing Therapy for HR+ Metastatic Breast Cancer

June 16th 2017

CDK4/6 Inhibitors for HR+ Metastatic Breast Cancer

June 16th 2017

FDA Approval of Ribociclib for Metastatic Breast Cancer

June 16th 2017

Dr. Freedman Discusses CNS Metastases in HER2+ Breast Cancer

June 15th 2017

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses brain metastases in patients with HER2-positive breast cancer.